Borosil Renewables Faces Scrutiny Over Undeployed Preferential Issue Funds

INDUSTRIAL-GOODSSERVICES
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Borosil Renewables Faces Scrutiny Over Undeployed Preferential Issue Funds
Overview

Borosil Renewables' Monitoring Agency Reports reveal over ₹674 Crore from preferential issues remain unutilized, parked in money market funds, while its German subsidiary faces insolvency proceedings. Though agencies confirm no deviation, the Bharuch expansion CapEx is significantly delayed.

📉 The Financial Deep Dive

The Numbers:

Borosil Renewables Limited's Monitoring Agency Reports from ICRA and CARE Ratings, submitted for the quarter ended December 31, 2025, detail the utilization of proceeds from preferential issues.

  • February 2025 Issue: Raised ₹517.66 Crore (revised from ₹700 Crore). Utilized: ₹185 Crore for GMB subsidiary liabilities, ₹29.60 Crore for Bharuch CapEx. Unutilized: ₹303.06 Crore for Bharuch CapEx, ₹0 for General Corporate Purposes.
  • October 2025 Issue: Raised ₹371.49 Crore (vs ₹376.02 Crore issue size). Utilized: ₹0 for CapEx/GCP. Unutilized: ₹371.49 Crore.
  • Total Unutilized (for CapEx/GCP): Approximately ₹674.55 Crore.

The Quality (Fund Deployment & Subsidiary Health):

A significant portion of funds raised for the solar glass expansion at Bharuch remains unutilized and is temporarily parked in various money market mutual funds, including Aditya Birla Sun Life, Kotak, HDFC, and ICICI Prudential MMFs. This strategy generates interest income but defers the intended capital expenditure.

Notably, ₹185 Crore from the February issue was allocated to address liabilities of its German subsidiary, GMB Glasmanufaktur Brandenburg GmbH, which has filed for insolvency in Germany. This diversion impacts the planned CapEx deployment.

Capital expenditure for the Bharuch solar glass expansion has seen minimal utilization (₹29.60 Crore), with a substantial ₹303.06 Crore pending.

CARE Ratings observed an 8% deviation in the allocation towards General Corporate Purpose for the October issue, attributed to under-subscription, with the shortfall to be funded by internal accruals.

Crucially, both ICRA and CARE Ratings have reported "no deviation" from the objects of the respective issues, indicating that the stated purposes remain the ultimate goal, despite deployment status and subsidiary issues.

Risks & Outlook:

  • Risks:
    • Continued delays in deploying funds for the Bharuch expansion could impact future production capacity targets and competitive positioning.
    • The financial implications and potential write-offs related to the insolvent German subsidiary pose a direct risk.
    • The current deployment in MMFs offers lower returns compared to the potential returns from completed expansion projects.
    • Investor confidence may be affected by perceived inefficiencies in capital allocation and overseas subsidiary management.
  • Outlook:
    Investors should closely monitor the commencement of significant capital expenditure at the Bharuch facility and any resolutions or further developments regarding the GMB subsidiary's insolvency. The company's ability to efficiently execute its expansion plans and manage its international operations will be critical in the coming quarters.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.